Written by Katarzyna Szklener
Published on Issue 1 Vol 3, 2023
Genetic alterations in the ALK gene occur in approximately 3-5% of cases of non-squamous non-small cell lung cancer (NSCLC). These rearrangements are critical in determining how cancer cells respond to treatment with ALK inhibitors. However, over time, some patients may develop resistance, leading to disease progression. In such cases, performing genetic analysis is crucial to detect new mutations that could be driving resistance, enabling healthcare providers to select the most appropriate next
Read More
Written by Kirti Amresh Gautam
Published on Issue 1 Vol 3, 2023
Breast cancer (BC) is the second leading cause of cancer-related deaths among women worldwide, and occasionally occurs in men. The majority of deaths related to breast cancer, over 90%, are due to delayed detection, which allows the disease to spread to other organs. The diagnostic process usually involves a biopsy, supported by imaging techniques such as MRI and CT scans, to confirm the diagnosis and guide treatment planning. This review examines various treatment strategies, including chemothe
Read More
Written by Dobrina Tsvetkova
Published on Issue 1 Vol 3, 2023
The focus of the present study was to evaluate the cytotoxic effects of novel peptide esters derived from galantamine—GAL-LEU and GAL-VAL—on the PC3 prostate cancer cell line. To assess the cytotoxicity of these compounds, the MTT assay, a method that quantifies cellular metabolic activity through the reduction of MTT to formazan, was used. PC3 cells were exposed to different concentrations (ranging from 1.875 μM to 30 μM) of the peptide esters in triplicate. The absorbance of the formazan produ
Read More
Written by Anshoo Agarwal
Published on Issue 1 Vol 3, 2023
Benign gallbladder disorders are frequently observed and generally resolve without long-term effects. However, some of these conditions are associated with an increased risk of gallbladder cancer, while others can lead to malignancy. This review aims to inform surgeons of the potential improvements in treatment strategies enabled by earlier recognition of GBC and to assist pathologists in refining histopathological assessments to reduce fatalities associated with delayed diagnoses. The immune ma
Read More
Written by Dalbir Singh
Published on Issue 1 Vol 3, 2023
Thiazolidin-4-ones exhibit a highly adaptable and privileged core structure, consisting of a five-membered heterocyclic ring with a sulfur atom and a cyclic amide bond. Recent research, especially in the last decade, has extensively explored the various biological activities of this scaffold, highlighting its potential therapeutic applications. Several key features, such as drug-likeness, compatibility for diversity-oriented synthesis, and sensitivity to the redox environment of tumors, make it
Read More
Written by Basma Nasr Hassan
Published on Issue 1 Vol 3, 2023
Heliomycin, a compound obtained from the secondary metabolites of actinomycetes bacteria, was tested for its anticancer effects, with tamoxifen serving as the reference drug. Flow cytometry, cell cycle analysis, and apoptosis assays were performed, alongside real-time RT-PCR to evaluate gene expression. The expression of CK-19 was examined by immunocytochemistry, while cytopathological changes were observed using H&E staining and electron microscopy. The results of real-time PCR showed that HER-
Read More
Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.
Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.